The Immune Response Corporation's Interim Phase II Data Suggest Both REMUNE And IR103 Stabilize CD4+ Cell Counts In Drug-Naive HIV Patients

... The Immune Response Corporation (OTC Bulletin Board: IMRP) today announced preliminary Phase II study results suggesting that both REMUNE(R) and IR103, its first and second generation HIV vaccine candidates, stabilize CD4+ T-cell counts compared with placebo in HIV patients who have not started antiretroviral (ARV) therapy. [click link for full article] ...